Compare APC & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APC | CMPS |
|---|---|---|
| Founded | 2025 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 892.9M | 724.5M |
| IPO Year | N/A | 2020 |
| Metric | APC | CMPS |
|---|---|---|
| Price | $18.43 | $9.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $21.75 | ★ $26.57 |
| AVG Volume (30 Days) | 125.3K | ★ 2.1M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.47 | N/A |
| Revenue Next Year | $4.20 | N/A |
| P/E Ratio | $25.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.08 | $2.25 |
| 52 Week High | $19.80 | $8.90 |
| Indicator | APC | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 47.05 | 81.17 |
| Support Level | $17.32 | $5.95 |
| Resistance Level | $19.01 | N/A |
| Average True Range (ATR) | 0.56 | 0.40 |
| MACD | -0.00 | 0.36 |
| Stochastic Oscillator | 45.51 | 84.89 |
Arko Petroleum Corp is a fuel distribution company. It operates through three reportable segments: i) Wholesale: Distributes fuel to gas stations, sub-wholesalers, and bulk purchasers, typically under long-term contracts on a cost-plus or consignment basis. ii) Fleet Fueling: Operates proprietary and third-party cardlock locations serving commercial and municipal fleets, and earns commissions from proprietary fuel card sales. iii) GPMP: Supplies fuel to ARKO Retail Sites at cost plus a fixed margin, charges fixed fees to certain sites. The company generates the majority of revenue from the Wholesale segment.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.